BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 16, 2016
View Archived Issues
Immunomedics terminates phase III PANCRIT-1 trial for clivatuzumab tetratexan
Read More
Adocia and Lilly present positive topline results from phase Ib study of BioChaperone Lispro
Read More
CTxT Pty patents PRMT5 inhibitors
Read More
Pierre Fabre describes FLT3, JAK2 and/or JAK3 inhibitors
Read More
NicOx patent discloses nitric oxide donors
Read More
CHDI Foundation divulges probes for imaging huntingtin protein
Read More
Blueprint Medicines and Roche enter worldwide collaboration in the field of cancer immunotherapy
Read More
Shionogi presents AMPK activators
Read More
HUYA Bioscience licenses ex-China rights to IDO inhibitors from Fudan University
Read More
Safety, tolerability and pharmacokinetics of LCB01-0371 in healthy volunteers
Read More
Aralez resubmits Yosprala NDA
Read More
Novel dual-target compounds inhibit inducible nitric oxide synthase and cannabinoid CB1 receptors
Read More
Orexigen announces strategic acquisition of all rights to Contrave in the U.S.
Read More
Takeda Pharmaceuticals U.S.A. announces new U.S. strategy and organization
Read More
Verona Pharma announces positive results from RPL-554 trial in asthma
Read More
ViDAC Pharma describes first-in-class VDAC/HK modulator for skin cancer
Read More
PF-06747775: a third-generation EGFR tyrosine kinase inhibitor
Read More
Xenon updates progress of pain collaborations with Genentech
Read More
ProMetic Life Sciences to explore use of PBI-4050 for scleroderma
Read More
Phase III data on padeliporfin di-potassium in low-risk prostate cancer
Read More
Boehringer Ingelheim seeks Japanese approval of idarucizumab in Japan
Read More
DSMB recommends continuation of phase II trial of lirilumab in elderly patients with AML
Read More
Regulatory agencies review Zydelig over serious adverse events in ongoing trials
Read More
18F-FACBC tracer as alternative to 11C-choline imaging in prostate cancer relapse
Read More
Johnson & Johnson launches JLINX, a new platform to promote scientific innovation
Read More